Diabetes medication sits at the center of this dementia and brain health question.
The diabetes medications most strongly linked to serious urinary tract infections are SGLT2 inhibitors — a class that includes Invokana (canagliflozin), Farxiga (dapagliflozin), Jardiance (empagliflozin), and Steglatro (ertugliflozin). These drugs work by forcing excess glucose out through the kidneys and into urine, which sounds clever in theory but creates a sugar-rich environment where bacteria and fungi thrive. The FDA has issued multiple safety communications about these drugs, identifying 19 cases of life-threatening urosepsis and pyelonephritis that started as ordinary UTIs — every one of those patients was hospitalized, and some ended up in the ICU or on dialysis. For older adults, particularly those managing both diabetes and cognitive decline, this risk deserves serious attention. A real-world observational study found UTI incidence of 33.49% among patients on SGLT2 inhibitors compared to just 11.72% in those not taking them — a 3.70 times higher risk.
UTIs in elderly patients can trigger delirium, accelerate cognitive decline, and lead to hospitalizations that compound existing health challenges. This article covers how these drugs create infection risk, what the latest research says about outcomes, who faces the greatest danger, and the difficult clinical tradeoff between stopping the medication and staying on it. A 2025 case report illustrates the problem vividly: a patient with no prior UTI history developed emphysematous pyelonephritis — a severe, life-threatening kidney infection — while taking dapagliflozin (Farxiga). When the patient resumed the medication after recovering, the pyelonephritis came back. That kind of pattern is exactly what has researchers and clinicians paying closer attention to the infection risks baked into this drug class.
Table of Contents
- Why Do SGLT2 Diabetes Medications Cause Urinary Tract Infections?
- FDA Warnings and the Escalation from UTIs to Life-Threatening Infections
- The Dementia Connection — Why UTIs Hit Older Adults Harder
- Should You Stop Taking an SGLT2 Inhibitor After a UTI?
- Legal Actions and What They Reveal About the Risk Landscape
- Practical Steps for Caregivers Managing SGLT2 Inhibitor Risks
- Where the Research Is Heading
- Conclusion
- Frequently Asked Questions
Why Do SGLT2 Diabetes Medications Cause Urinary Tract Infections?
The mechanism is straightforward and, in hindsight, almost predictable. SGLT2 inhibitors block a protein in the kidneys responsible for reabsorbing glucose back into the bloodstream. Instead of being recycled, that glucose gets dumped into the urine. The result is glycosuria — persistently sugar-laden urine — which provides an ideal growth medium for the bacteria and yeast that cause urinary tract infections. It is the pharmacological equivalent of leaving a bowl of sugar water out and being surprised when it attracts ants. What makes this different from the occasional UTI that anyone might develop is the persistence of the risk.
As long as a patient takes the medication, their urine remains glucose-enriched. Compare this to, say, a short course of antibiotics that might temporarily disrupt the urinary microbiome — SGLT2 inhibitors create an ongoing, daily shift in the urinary environment. A 2025 European Heart Journal study following 61,606 patients on these drugs found that 3,921 of them — 6.36% — developed at least one UTI during follow-up. That might sound modest until you consider the severity: patients who developed UTIs had a 3.18 times higher risk of cardiovascular events and a 2.51 times higher risk of renal events compared to those who did not. The risk is not evenly distributed. Female sex, advanced age, higher HbA1c levels, higher BMI, prior UTI history, urinary obstruction, and longer duration of type 2 diabetes all increase the likelihood of developing a UTI on these medications. For an elderly woman with long-standing diabetes and a history of bladder infections, the calculus around starting an SGLT2 inhibitor looks quite different than it does for a younger male patient newly diagnosed with type 2 diabetes.
FDA Warnings and the Escalation from UTIs to Life-Threatening Infections
The FDA did not simply note a mild uptick in bladder infections and move on. The agency revised the labels on all SGLT2 inhibitors to include specific warnings about serious urinary tract infections, including urosepsis (a UTI that has progressed to sepsis) and pyelonephritis (infection of the kidneys). The 19 cases the FDA flagged were not ambiguous — these were patients who started with what might have seemed like a routine UTI and ended up fighting for their lives in hospital beds. However, the story got worse. In August 2018, the FDA issued a separate warning about Fournier’s gangrene linked to SGLT2 inhibitors. Fournier’s gangrene is necrotizing fasciitis of the perineum — rapidly spreading tissue death in the genital and perianal region.
The FDA initially identified 12 cases between March 2013 and May 2018, but that number later climbed to 55 confirmed cases. The time from starting the drug to onset ranged wildly, from as few as 5 days to as long as 49 months. Every single patient required surgical debridement — the cutting away of dead and infected tissue. Fournier’s gangrene carries a mortality rate of up to 88% in some reported case series, though outcomes depend heavily on how quickly it is caught and treated. It is worth noting that Fournier’s gangrene is exceptionally rare in the general population, which is part of what made the SGLT2 connection so alarming to the FDA. If you or a family member is on one of these medications and develops unusual pain, tenderness, swelling, or redness in the genital area accompanied by fever, that warrants an emergency room visit — not a wait-and-see approach. This is one of those situations where the downside of overreacting is trivial compared to the downside of underreacting.
The Dementia Connection — Why UTIs Hit Older Adults Harder
For readers of this site, there is an additional layer of concern that most diabetes-focused discussions skip entirely. Urinary tract infections in elderly adults — particularly those with dementia or mild cognitive impairment — can trigger acute delirium, sudden behavioral changes, increased confusion, and falls. A caregiver who notices their loved one suddenly becoming agitated, disoriented, or uncharacteristically confused may not immediately think “urinary tract infection,” but it is one of the most common culprits. The problem compounds when the person with dementia cannot reliably communicate symptoms. The early signs of a UTI — burning during urination, increased urgency, lower abdominal discomfort — require self-reporting.
A person with moderate to advanced dementia may not be able to articulate these symptoms, meaning the infection progresses silently until it manifests as behavioral changes, fever, or worse. If that person is also on an SGLT2 inhibitor, the baseline UTI risk is already elevated, and the window between a treatable infection and a dangerous one may be shorter than anyone realizes. Hospitalizations from severe UTIs carry their own cognitive risks for dementia patients. The disruption of routine, exposure to unfamiliar environments, potential use of sedating medications, and the physiological stress of sepsis can all accelerate cognitive decline. A hospitalization that a younger, cognitively healthy patient might recover from fully can represent a permanent step down in function for someone with Alzheimer’s or vascular dementia.
Should You Stop Taking an SGLT2 Inhibitor After a UTI?
This is where the clinical picture gets genuinely complicated, and the answer is not what most people expect. The 2025 European Heart Journal study — the largest of its kind, covering over 61,000 patients — found that discontinuing an SGLT2 inhibitor after a UTI was associated with a 1.35 times higher risk of cardiovascular and renal events compared to continuing the medication. Meanwhile, the risk of recurrent UTI was similar whether patients continued or stopped the drug. In other words, stopping the medication after a UTI may actually leave patients worse off overall. The cardiovascular and kidney benefits of SGLT2 inhibitors — which are substantial and well-documented — appear to outweigh the infection risk for most patients, even those who have already experienced a UTI.
The study found that 32.31% of patients discontinued their SGLT2 inhibitor after developing a UTI, suggesting that a significant number of patients and physicians are making a decision that the data does not support. That said, this is a population-level finding, and individual circumstances matter enormously. A frail 85-year-old with advanced dementia, recurrent UTIs, and a history of sepsis is in a very different situation than a 60-year-old with well-controlled diabetes and a single mild bladder infection. The conversation with a prescribing physician should weigh the specific cardiovascular and renal benefits the patient is getting from the SGLT2 inhibitor against their individual infection risk profile. There is no universal right answer, but there is a wrong one: making the decision based on fear alone without looking at the full picture.
Legal Actions and What They Reveal About the Risk Landscape
Lawsuits can serve as a rough barometer of how seriously adverse effects are being taken — not as medical evidence, but as a signal of real-world harm. The Invokana multidistrict litigation (MDL) included 1,208 cases before closing in 2023. The Farxiga MDL shut down in 2020 without verdicts or settlements. Johnson & Johnson has settled some individual Invokana lawsuits, but hundreds remain active. Jardiance lawsuits have been filed, but none have been litigated or settled as of the latest available information.
The legal landscape matters here not because a lawsuit proves a drug is dangerous — the clinical data does that on its own — but because it signals the gap between what regulators warned about and what patients actually experienced. Many of these lawsuits allege that manufacturers knew about the infection risks earlier than they disclosed, or that they failed to adequately warn physicians and patients. Whether or not those allegations hold up in court, they underscore a pattern that patients and caregivers should take seriously: the label warnings exist because real people were harmed, and the full scope of that harm took years to become visible. One limitation worth noting is that closed MDLs and dismissed cases do not necessarily mean the drugs were found safe. MDLs can close for procedural reasons, and individual lawsuits can settle confidentially. The absence of a public verdict is not the same as vindication.
Practical Steps for Caregivers Managing SGLT2 Inhibitor Risks
If a loved one with dementia or cognitive impairment is prescribed an SGLT2 inhibitor, proactive monitoring becomes essential. Keep a log of urinary habits — frequency, any visible changes in urine color or odor, and episodes of incontinence that deviate from the baseline. Watch for non-verbal signs of discomfort like increased restlessness, guarding the lower abdomen, or resisting toileting assistance.
Request periodic urinalysis at routine medical visits rather than waiting for symptoms to emerge. Hydration is a practical countermeasure that is often overlooked. Adequate fluid intake helps dilute the glucose concentration in urine and promotes more frequent urination, which flushes bacteria before they can establish an infection. For dementia patients who may not recognize thirst or remember to drink, structured hydration — offering water at regular intervals throughout the day — is a simple intervention that can meaningfully reduce UTI risk.
Where the Research Is Heading
The 2025 European Heart Journal study represents a shift in how clinicians are thinking about SGLT2 inhibitors and infection risk. Rather than treating UTIs as a reason to abandon an otherwise beneficial drug, the emerging consensus is moving toward better infection surveillance and management while maintaining the cardiovascular and renal protections these medications provide. Future research is expected to focus on identifying which patient subgroups face the highest infection risk so that prescribing can be better tailored from the start.
For the aging population — where diabetes, cognitive decline, and UTI vulnerability frequently overlap — this research direction is particularly important. The goal is not to choose between heart and kidney protection on one hand and infection safety on the other, but to develop protocols that deliver both. Until that work matures, the responsibility falls on patients, caregivers, and prescribers to weigh the tradeoffs with clear eyes and good data rather than defaulting to either reflexive fear or uncritical trust in a prescription.
Conclusion
SGLT2 inhibitors — Invokana, Farxiga, Jardiance, and Steglatro — are effective diabetes medications that carry a well-documented and FDA-acknowledged risk of serious urinary tract infections, including urosepsis, pyelonephritis, and the rare but devastating Fournier’s gangrene. Real-world data shows UTI rates more than three times higher among SGLT2 users compared to non-users, and for older adults with dementia, these infections carry additional dangers including delirium, hospitalization-related cognitive decline, and communication barriers that delay diagnosis. The most important takeaway from the latest research is counterintuitive: stopping the medication after a UTI may not be the safest choice.
The 2025 European Heart Journal data suggests that the cardiovascular and renal benefits of continuing outweigh the infection risk for most patients. But “most patients” is not “all patients,” and individual decisions should be made with a physician who understands the full clinical picture — especially when cognitive impairment is part of that picture. Caregivers should advocate for proactive UTI monitoring, maintain good hydration practices, and ensure that any prescribing decision accounts for the unique vulnerabilities of the person in their care.
Frequently Asked Questions
Which specific diabetes medications are linked to serious UTIs?
SGLT2 inhibitors, including Invokana (canagliflozin), Farxiga (dapagliflozin), Jardiance (empagliflozin), and Steglatro (ertugliflozin). These drugs force excess glucose into the urine, creating conditions that promote bacterial growth.
How much do SGLT2 inhibitors increase UTI risk?
A real-world observational study found UTI incidence of 33.49% in the SGLT2 group versus 11.72% in non-users — a 3.70 times higher risk. A larger 2025 study of over 61,000 patients found a 6.36% UTI rate during follow-up.
Should I stop taking my SGLT2 inhibitor if I get a UTI?
Not necessarily. The 2025 European Heart Journal study found that discontinuing after a UTI was associated with 1.35 times higher cardiovascular and renal risks, while recurrent UTI risk was similar whether patients continued or stopped. Discuss your specific situation with your doctor.
What is Fournier’s gangrene and how is it related to these drugs?
Fournier’s gangrene is necrotizing fasciitis of the genital and perianal region. The FDA identified 55 cases linked to SGLT2 inhibitors. It requires emergency surgical treatment and carries a mortality rate of up to 88% in severe cases. Any unusual pain, swelling, or redness in the genital area while on these medications warrants immediate medical attention.
Are older adults with dementia at special risk from SGLT2-related UTIs?
Yes. UTIs in elderly dementia patients can trigger delirium, behavioral changes, and increased confusion. These patients may also be unable to communicate early symptoms, allowing infections to progress to dangerous stages before detection.
Can anything reduce UTI risk while staying on an SGLT2 inhibitor?
Adequate hydration helps dilute urinary glucose and promotes flushing of bacteria. Regular urinalysis monitoring, attention to hygiene, and prompt treatment of early symptoms can also reduce the risk of a minor infection becoming a serious one.
You Might Also Like
- The BP Medication That Can Cause Your Ankles to Swell
- The Blood Pressure Pill That Can Cause Dangerous Potassium Levels
- The Diabetes Drug That Also Protects Your Heart — Doctors Are Amazed
For more, see CDC — Alzheimer’s and Dementia.
